Ca2+ responses to thyrotropin-releasing hormone and angiotensin II: The role of plasma membrane integrity and effect of G11α protein overexpression on homologous and heterologous desensitization

Cell Biochemistry and Function

Volumn 26, Issue 2, 2008, Pages 264-274

  Ostasov, Pavel ^a,b   Krusek, Jan ^a   Durchankova, Dana ^a,b   Svoboda, Petr ^a,b   Novotny, Jiri ^a,b  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Angiotensin II receptor; Ca2+ response; Desensitization; Gq G11 protein; Membrane domain; TRH receptor

Indexed keywords

ANGIOTENSIN II; CALCIUM; CHOLESTEROL; G PROTEIN COUPLED RECEPTOR; PROTIRELIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; PROTIRELIN RECEPTOR;

ARTICLE; CELL CULTURE; CELL MEMBRANE; CELL STRAIN HEK293; CONTROLLED STUDY; ELECTROPHORESIS; EMBRYO; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; BIOSYNTHESIS; CALCIUM SIGNALING; DOSE RESPONSE; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; METABOLISM; PHYSIOLOGY; TEMPERATURE; TIME;

ANGIOTENSIN II; CALCIUM; CALCIUM SIGNALING; CELL MEMBRANE; CELLS, CULTURED; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HUMANS; RECEPTORS, THYROTROPIN-RELEASING HORMONE; TEMPERATURE; THYROTROPIN-RELEASING HORMONE; TIME FACTORS; TRANSFECTION;

EID: 40649090136     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1453     Document Type: Article

References (46)

1. Sun Y, Lu X, Gershengorn MC. Thyrotropin-releasing hormone receptors-similarities and differences. J Mol Endocrinol 2003; 30: 87-97.
2. Thomas WG, Mendelsohn FA. Angiotensin receptors: form and function and distribution. Int J Biochem Cell Biol 2003; 35: 774-779.
3. Anderson L, Alexander CL, Faccenda E, Eidne KA. Rapid desensitization of the thyrotropin-releasing hormone receptor expressed in single human embryonal kidney 293 cells. Biochem J 1995; 311(Pt 2): 385-392.
4. Kornfeld M, Gutierrez AM, Persson AE, Salomonsson M. Angiotensin II induces a tachyphylactic calcium response in the rabbit afferent arteriole. Acta Physiol Scand 1997; 160: 165-173.
5. Yu R, Hinkle PM. Desensitization of thyrotropin-releasing hormone receptor-mediated responses involves multiple steps. J Biol Chem 1997; 272: 28301-28307.
6. Iglesias AG, Suarez C, Feierstein C, Diaz-Torga G, Becu-Villalobos D. Desensitization of angiotensin II: effect on. Am J Physiol Endocrinol Metab 2001; 280: E462-E470.
7. Chini B, Parenti M. G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there? J Mol Endocrinol 2004; 32: 325-338.
8. Ostrom RS, Insel PA. The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology. Br J Pharmacol 2004; 143: 235-245.
9. London E, Brown DA. Insolubility of lipids in triton X-100: physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim Biophys Acta 2000; 1508: 182-195.
10. Schlegel A, Volonte D, Engelman JA, et al. Crowded little caves: structure and function of caveolae. Cell Signal 1998; 10: 457-463.
11. Shenoy-Scaria AM, Gauen LK, Kwong J, Shaw AS, Lublin DM. Palmitylation of an amino-terminal cysteine motif of protein tyrosine kinases p561ck and p59fyn mediates interaction with glycosyl-phosphatidylinositol-anchored proteins. Mol Cell Biol 1993; 13: 6385-6392.
12. Goligorsky MS, Li H, Brodsky S, Chen J. Relationships between caveolae and eNOS: everything in proximity and the proximity of everything. Am J Physiol Renal Physiol 2002; 283: F1-F10.
13. Lisanti MP, Sargiacomo M, Scherer PE. Purification of caveolae-derived membrane microdomains containing lipid-anchored signaling molecules, such as GPI-anchored proteins, H-Ras, Src-family tyrosine kinases, eNOS, and G-protein alpha-, beta-, and gamma-subunits. Methods Mol Biol 1999; 116: 51-60.
14. Rybin VO, Pak E, Alcott S, Steinberg SF. Developmental changes in beta2-adrenergic receptor signaling in ventricular myocytes: the role of Gi proteins and caveolae microdomains. Mol Pharmacol 2003; 63: 1338-1348.
15. Moravcova Z, Rudajev V, Stohr J, et al. Long-term agonist stimulation of LP prostanoid receptor depletes the cognate G(s)alpha protein in membrane domains but does not change the receptor level. Biochim Biophys Acta 2004; 1691: 51-65.
16. Rudajev V, Novotny J, Hejnova L, Milligan G, Svoboda P. Dominant portion of thyrotropin-releasing hormone receptor is excluded from lipid domains. Detergent-resistant and detergent-sensitive pools of TRH receptor and Gqalpha/G11alpha protein. J Biochem (Tokyo) 2005; 138: 111-125.
17. Fujita T, Toya Y, Iwatsubo K, et al. Accumulation of molecules involved in alpha1-adrenergic signal within caveolae: caveolin expression and the development of cardiac hypertrophy. Cardiovasc Res 2001; 51: 709-716.
18. Head BP, Patel HH, Roth DM, et al. G-protein-coupled receptor signaling components localize in both sarcolemmal and intracellular caveolin-3-associated microdomains in adult cardiac myocytes. J Biol Chem 2005; 280: 31036-31044.
19. Latif R, Ando T, Daniel S, Davies TF. Localization and regulation of thyrotropin receptors within lipid rafts. Endocrinology 2003; 144: 4725-4728.
20. Lamb ME, Zhang C, Shea T, Kyle DJ, Leeb-Lundberg LM. Human B1 and B2 bradykinin receptors and their agonists target caveolae-related lipid rafts to different degrees in HEK293 cells. Biochemistry 2002; 41: 14340-14347.
21. Chun M, Liyanage UK, Lisanti MP, Lodish HF. Signal transduction of a G protein-coupled receptor in caveolae: colocalization of endothelin and its receptor with caveolin. Proc Natl Acad Sci USA 1994; 91: 11728-11732.
22. Kaiser RA, Oxhorn BC, Andrews G, Buxton IL. Functional compartmentation of endothelial P2Y receptor signaling. Circ Res 2002; 91: 292-299.
23. Wyse BD, Prior IA, Qian H, et al. Caveolin interacts with the angiotensin II type 1 receptor during exocytic transport but not at the plasma membrane. J Biol Chem 2003; 278: 23738-23746.
24. Bourova L, Novotny J, Svoboda P. Resolution and identification of Gq/G11alpha and Gialpha/Goalpha proteins in brown adipose tissue: effect of cold acclimation. J Mol Endocrinol 1999; 23: 223-229.
25. Wang SS, Thompson SH. Measurement of changes in functional muscarinic acetylcholine receptor density in single neuroblastoma cells using calcium release kinetics. Cell Calcium 1994; 15: 483-496.
26. Hus-Citharel A, Bouby N, Marchetti J, et al. Desensitization of type 1 angiotensin II receptor subtypes in the rat kidney. Endocrinology 2001; 142: 4683-4692.
27. Suarez C, Tornadu IG, Cristina C, et al. Angiotensin and calcium signaling in the pituitary and hypothalamus. Cell Mol Neurobiol 2002; 22: 315-333.
28. 2+ response to thyrotropin-releasing hormone. Life Sci 1999; 65: 889-900.
29. Vatner DE, Asai K, Iwase M, et al. Overexpression of myocardial Gsalpha prevents full expression of catecholamine desensitization despite increased beta-adrenergic receptor kinase. J Clin Invest 1998; 101: 1916-1922.
30. 3H]N6-(R)-phenylisopropyladenosine binding to pig brain cortical membranes by changes of membrane fluidity and of medium physicochemical characteristics. Eur J Pharmacol 1992; 225: 7-14.
31. Ochsner M. Ca2+ transient, cell volume, and microviscosity of the plasma membrane in smooth muscle. Biochem Pharmacol 1997; 53: 1765-1777.
32. Tillman TS, Cascio M. Effects of membrane lipids on ion channel structure and function. Cell Biochem Biophys 2003; 38: 161-190.
33. Cezanne L, Lecat S, Lagane B, et al. Dynamic confinement of NK2 receptors in the plasma membrane. Improved FRAP analysis and biological relevance. J Biol Chem 2004; 279: 45057-45067.
34. Danielsen EM, Hansen GH. Lipid rafts in epithelial brush borders: atypical membrane microdomains with specialized functions. Biochim Biophys Acta 2003; 1617: 1-9.
35. Ishizaka N, Griendling KK, Lassegue B, Alexander RW. Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. Hypertension 1998; 32: 459-466.
36. Zuo L, Ushio-Fukai M, Ikeda S, Hilenski L, Patrushev N, Alexander RW. Caveolin-1 is essential for activation of Rac1 and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells: role in redox signaling and vascular hypertrophy. Arterioscler Thromb Vasc Biol 2005; 25: 1824-1830.
37. Olivares-Reyes JA, Shah BH, Hernandez-Aranda J, et al. Agonist-induced interactions between angiotensin AT1 and epidermal growth factor receptors. Mol Pharmacol 2005; 68: 356-364.
38. Matousek P, Durchankova D, Svandova I, Novotny J, Svoboda P. Agonist-induced tyrosine phosphorylation of Gq/G11 alpha requires the intact structure of membrane domains. Biochem Biophys Res Commun 2005; 328: 526-532.
39. de Weerd WF, Leeb-Lundberg LM. Bradykinin sequesters B2 bradykinin receptors and the receptor-coupled Galpha subunits Galphaq and Galphai in caveolae in DDT1 MF-2 smooth muscle cells. J Biol Chem 1997; 272: 17858-17866.
40. Costa MJ, Song Y, Macours P, et al. Sphingolipid-cholesterol domains (lipid rafts) in normal human and dog thyroid follicular cells are not involved in thyrotropin receptor signaling. Endocrinology 2004; 145: 1464-1472.
41. Oh P, Schnitzer JE. Segregation of heterotrimeric G proteins in cell surface microdomains. G(q) binds caveolin to concentrate in caveolae, whereas G(i) and G(s) target lipid rafts by default. Mol Biol Cell 2001; 12: 685-698.
42. Garcia-Marcos M, Tandel S, Pochet S, et al. Cholesterol depletion perturbs calcium handling by rat submandibular glands. J Cell Physiol 2005; 203: 429-438.
43. 2+ exchanger 1 association with caveolin-1 and -2 in C6 glioma cells. IUBMB Life 2004; 56: 621-627.
44. Pang Y, Zhu H, Wu P, Chen J. The characterization of plasma membrane Ca2+-ATPase in rich sphingomyelin-cholesterol domains. FEBS Lett 2005; 579: 2397-2403.
45. 2+ signaling microdomains: platforms for the assembly and regulation of TRPC channels. Trends Pharmacol Sci 2006; 27: 25-32.
46. Cornea A, Janovick JA, Stanislaus D, Conn PM. Redistribution of G(q/11)alpha in the pituitary gonadotrope in response to a gonadotropin- releasing hormone agonist. Endocrinology 1998; 139: 397-402.